PTC Therapeutics Inc Corporate Call - Translarna™Study 045 and Clinical Update Transcript
Ladies and gentlemen, thank you for standing by and welcome to the PTC Study 045 review call. (Operator Instructions)
I'd now like to hand the conference over to your host today, Mr. Stuart Peltz, Chief Executive Officer. Please go ahead.
Thank you, and welcome. I'm now going to take you through the Study 045 dystrophin study results. As a reminder, this is a biomarker study that was recommended by the FDA to support a potential accelerated approval, specifically for the U.S.
Shown on Slide 2 are our forward-looking statements. So today, I will be making forward-looking statements. So I ask you to please refer to the SEC filings for our forward-looking statements.
Let's go to Slide 3, which is our study design. And as you remember, we enrolled 20 boys, aged 2 to 7 years old, with nonsense mutation Duchenne muscular dystrophy. The boys received baseline biopsies prior to the initiation of treatment, and follow-up biopsy scheduled at 40 weeks following
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |